Announced
Completed
Legend Capital led a $107m Series E round in MicuRx.
Synopsis
Legend Capital, an independent venture capital firm, led a $107m Series E round in MicuRx Pharmaceuticals, which discovers and develops novel antibiotics to combat drug-resistant bacterial infections. MicuRx attracted a slew of investors including China Merchants Securities, Korea Investment Partners, Yingke PE, Founder H Fund, Zhongtai Ventures, and Detong Capital. The fresh proceeds will be used for new drug development, global clinical trials, pipeline advancement and drug commercialization in China.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.